Type 1 cannabinoid receptor mapping with [(18)F]MK-9470 PET in the rat brain after quinolinic acid lesion: a comparison to dopamine receptors and glucose metabolism by Casteels, Cindy et al.
ORIGINAL ARTICLE
Type 1 cannabinoid receptor mapping with [18F]MK-9470
PET in the rat brain after quinolinic acid lesion:
a comparison to dopamine receptors and glucose metabolism
Cindy Casteels & Emili Martinez & Guy Bormans &
Lluïsa Camon & Núria de Vera & Veerle Baekelandt &
Anna M. Planas & Koen Van Laere
Received: 16 April 2010 /Accepted: 15 July 2010
# Springer-Verlag 2010
Abstract
Purpose Several lines of evidence imply early alterations in
metabolic, dopaminergic and endocannabinoid neurotrans-
mission in Huntington’s disease (HD). Using [18F]MK-9470
and small animal PET, we investigated cerebral changes in
type 1 cannabinoid (CB1) receptor binding in the quinolinic
acid (QA) rat model of HD in relation to glucose
metabolism, dopamine D2 receptor availability and
amphetamine-induced turning behaviour.
Methods Twenty-one Wistar rats (11 QA and 10 shams) were
investigated. Small animal PET acquisitions were conducted
on a Focus 220with approximately 18MBq of [18F]MK-9470,
[18F]FDG and [11C]raclopride. Relative glucose metabolism
and parametric CB1 receptor and D2 binding images were
anatomically standardized to Paxinos space and analysed
voxel-wise using Statistical Parametric Mapping (SPM2).
Results In the QA model, [18F]MK-9470 uptake, glucose
metabolism and D2 receptor binding were reduced in the
ipsilateral caudate-putamen by 7, 35 and 77%, respectively
(all p<2.10−5), while an increase for these markers was
observed on the contralateral side (>5%, all p<7.10−4).
[18F]MK-9470 binding was also increased in the cerebel-
lum (p=2.10−5), where it was inversely correlated to the
number of ipsiversive turnings (p=7.10−6), suggesting that
CB1 receptor upregulation in the cerebellum is related to a
better functional outcome. Additionally, glucose metabolism
was relatively increased in the contralateral hippocampus,
thalamus and sensorimotor cortex (p=1.10−6).
Conclusion These data point to in vivo changes in
endocannabinoid transmission, specifically for CB1 recep-
tors in the QA model, with involvement of the caudate-
putamen, but also distant regions of the motor circuitry,
including the cerebellum. These data also indicate the
occurrence of functional plasticity on metabolism, D2 and
CB1 neurotransmission in the contralateral hemisphere.
Keywords Type 1 cannabinoid receptor . Small animal
PET. QA . Huntington’s disease . [18F]MK-9470
Introduction
Huntington’s disease (HD) is a devastating genetic neuro-
degenerative disorder, clinically characterized by involun-
tary movements, emotional disturbances and cognitive
impairments. HD is caused by a CAG repeat expansion
within exon 1 of the HD gene on chromosome 4 [1]. The
mutated HD gene encodes an extended polyglutamine
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stretch in the N-terminal domain of the huntingtin (htt)
protein, which results in widespread neuronal degeneration
preferentially within the striatum [2]. Despite the discovery
of the genetic mutation associated with HD, the function of
the abnormal gene product and the pathogenic mechanisms
of the disease are still unknown.
Dysregulation of cannabinoid-mediated control of
striatal function might play a critical role in the
development of HD symptoms [3]. One of the earliest
neurochemical alterations observed in HD patients is the
loss of type 1 cannabinoid (CB1) receptor binding in the basal
ganglia, an alteration that significantly precedes the
development of identifiable striatal neuropathology [4].
Likewise, CB1 receptor mRNA levels were decreased in
the absence of neuronal loss in the lateral striatum, cortex
and hippocampus of transgenic mouse models of HD [5–9].
In the HD94 transgenic mice also decreases in the number of
basal ganglia-specific binding sites and the activation of
guanosine triphosphate (GTP)-binding proteins by CB1
receptor agonists were noticed [5]. Loss of CB1 receptors
in the basal ganglia not only occurred in transgenic mice
HD models, but also in rats after local intrastriatal
application of 3-nitropropionic acid (3-NP), a toxin that
reproduces the mitochondrial complex II deficiency
characteristic of HD patients [10]. Delaying the onset of
HD symptoms by enriched environments has been shown
to selectively slow down the loss of CB1 receptors in
experimental HD [11].
In normal conditions, CB1 receptors are abundantly
distributed in different structures of the brain, controlling
motor, cognition, emotional and sensory functions [12]. CB1
receptors encompass together with a family of plant-derived,
synthetic or endogenous compounds the endocannabinoid
system (ECS). The ECS is a modulatory system that
interacts with and regulates functioning of other neurotrans-
mitter systems such as glutamate and γ-aminobutyric acid
(GABA) [13].
So far, only in vitro and ex vivo data on the ECS exist in
experimental HD. Studies of CB1 receptor changes in
experimental HD have focused on the basal ganglia,
hippocampus and motor cortex, but have not assessed other
brain regions [7, 9]. Also unknown is whether CB1 receptor
levels are changed in vivo. In vivo imaging of CB1
receptors in the rat brain has recently become feasible due
to the development of a CB1-selective radioligand, [
18F]
MK-9470 [14, 15].
A well-characterized and frequently used rat model of
HD relies on the use of quinolinic acid (QA). QA is an
endogenous metabolite in the brain that results in the
degeneration of GABAergic striatonigral and striatopallidal
projection neurons [16] with the relative [10] sparing of
interneurons [17] after intrastriatal injection, a cellular
pathology remarkably similar to that in patients with HD.
In this study, we have characterized the QA lesion rat
model of HD in vivo with respect to CB1 receptor binding
using [18F]MK-9470 and small animal positron emission
tomography (PET) imaging. Also, dopamine D2 receptor
availability and glucose metabolism, all shown to be altered
(early) in patients and animal models of HD [18, 19], were
investigated in the same animals and correlated to the
regional CB1 receptor status.
Material and methods
Animals
Experiments were conducted on 21 female Wistar rats
(Charles River, France) weighing 160–170 g at the start of
the experiment. All animals were housed three to a cage, at
an average room temperature of 22°C and a 12-h light/dark
cycle. Food and water were given ad libitum. The research
protocol was approved by the local Animal Ethics
Committees of the Universities of Leuven and Barcelona
and was according to European Ethics Committee guidelines
(decree 86/609/EEC).
Striatal quinolinic lesion
All surgical procedures were performed under 1.5%
halothane anaesthesia (4% during the induction period),
at a rate of 1.5 ml/min. All rats were placed in a
stereotactic head frame (David Kopf Instruments,
Tujunga, CA, USA) [20], and a single unilateral hole
was drilled in the skull over the left striatum using the
bregma as reference. The neurotoxic and sham lesions in
the left striatum were made by injecting 1 μl of QA (n=11,
240 nmol) or phosphate-buffered saline (PBS) (n=10, pH
7.4), respectively, at the following coordinates: anteroposte-
rior +0.2 mm, lateral +2.8 mm and dorsoventral −4.5 mm
[21]. The rate of infusion was 0.5 μl/min. After the injection,
the needle was left in place for an additional 5 min before
being slowly withdrawn from the brain.
Behavioural testing and weight
To assess toxin efficacy, the presence of QA-specific
stereotypes was assessed in QA-lesioned rats after recovering
using digital recording (Videotrack 2000, View Point, Lyon,
France) [22]. Briefly, each animal (immediately after
recovering from anaesthesia) was introduced into an indi-
vidual cage (33.3×33.3 cm), in a soundproof room, and the
behavioural activity was digitally recorded for a 3-h period.
Digital records were analysed by a well-trained researcher
evaluating the presence of QA-related stereotypes (head
nodding, circling and rolling behaviour). All QA-treated rats
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developed these stereotypes. Four weeks post-lesioning
amphetamine-induced asymmetric rotational behaviour was
monitored [23]. Amphetamine sulphate, supplied by the
Ministry of Health of Spain, was injected intraperitoneally
(i.p.) at a dose of 4 mg/kg free base. For each test, 5 min after
amphetamine administration, the total number of complete
turns clockwise and anticlockwise was counted over 30 min.
The direction ipsilateral to the lesion is considered as positive.
The analysis of amphetamine tests was based on net
ipsilateral turns (defined as anticlockwise turning in cases of
a left-sided injection). Additionally, changes in body weight
were measured before lesioning, 24 h and 4 weeks after.
Radiotracer synthesis
CB1 receptor imaging was performed in all animals (n=21)
using the radioligand [18F]MK-9470 (N-[2-(3-cyano-phe-
nyl)-3-(4-(2-[18F]fluorethoxy)phenyl)-1-methylpropyl]-2-
(5-methyl-2-pyridyloxy)-2-methylproponamide), which is
characterized by high specificity and high affinity for the
CB1 receptor (rat IC50 0.9 nM) [14]. The precursor for
tracer synthesis was obtained from Merck Research Labs
(West Point, PA, USA) and labelling was performed using an
[18F]ethylbromide procedure as described previously [14].
The final product was obtained after high-performance liquid
chromatography separation and had a radiochemical
purity >95%. Specific activity was on average 219 GBq/
μmol (specific activity range: 53–606 GBq/μmol). The tracer
was administered in a sterile solution of 5 mM sodium acetate
buffer pH 5.5 containing 6% of ethanol [24].
Functional images of the striatal dopamine system were
obtained from each surviving rat using the D2 receptor
radioligand [11C]raclopride (n=20) [25], while glucose
metabolism was assessed using [18F]FDG (n=20). [11C]
Raclopride was obtained by methylating the corresponding
nor-precursor with [11C]methyl triflate, whereas [18F]FDG
was prepared by using an Ion Beam Applications [18F]FDG
synthesis module. Approximately 18 MBq (500 μCi) of
each radioligand (specific activity range: 53–760 GBq/
μmol; injection volume: 500 μl) were injected into the tail
vein using an infusion needle set.
Data acquisition
Small animal PET imaging was performed using a lutetium
oxyorthosilicate detector-based tomograph (microPET
Focus 220, Siemens Medical Solutions USA, Inc.,
Malvern, PA, USA), which has a transaxial resolution of
1.35 mm in full-width at half-maximum. Data were acquired
in a 128×128×95 matrix with a pixel width of 0.475 mm and
a slice thickness of 0.796 mm. The coincidence windowwidth
was set at 6 ns. Before imaging, the rats were anaesthetized
with an i.p. injection of 50 mg of sodium pentobarbital
(Nembutal, Ceva Sante Animale, Brussels, Belgium) per
kilogram of body weight.
Imaging studies were performed on age-matched
animals within 11–13 weeks post-lesioning for [18F]
MK-9470, 16–18 weeks post-lesioning for [18F]FDG and
15–25 weeks post-lesioning for [11C]raclopride. Dynamic
60-min [18F]MK-9470 and [11C]raclopride acquisitions
were started immediately after tracer injection (frame
duration: 4×15 s, 4×60 s, 5×180 s, 8×300 s), while
[18F]FDG measurements were obtained during 40 min
starting 1 h after injection. Animals were scanned after
overnight fasting for [18F]MK-9470 and [18F]FDG. The
acquisition timing rationale and kinetics of the radio-
ligands in rats have been described previously [24, 26].
Sinograms were reconstructed using filtered backprojec-
tion (FBP). No corrections were made for attenuation or
scatter.
Small animal PET data processing and Statistical
Parametric Mapping (SPM)
Parametric images based on standardized uptake values (SUV)
[activity concentration (MBq/ml) × body mass(g)/injected
dose (MBq)] were generated as a measure of absolute CB1
receptor binding [14, 27]. No significant differences in body
weight or injected activity were present between QA- and
PBS-infused rats. We investigated absolute as well as relative
uptake. Relative [18F]MK-9470 uptake was expressed as
SUV values normalized on whole-brain SUV. Parametric D2
binding index (BI) images, representing D2 receptor avail-
ability, were constructed by reference to the cerebellum using
the Ichise multilinear reference tissue model 2 (MRTM2)
module in PMOD [28]. Relative regional glucose metabolism
was determined by count normalizing [18F]FDG data to the
whole-brain uptake. The within-subject test-retest variability
of our imaging procedures is in a magnitude consistent with
human data, i.e. <15% [15, 24, 29].
To obtain maximal use of image information without a
priori knowledge, images were analysed on a voxel-by-voxel
basis using SPM2. The procedure of spatial normalization and
its validation have been described previously [24]. This
methodology allows reporting results in coordinates directly
corresponding to the Paxinos coordinate system for the rat
brain.
SPM analysis was carried out using a categorical subject
design (conditions: disease vs controls) on parametric [18F]
MK-9470 and [11C]raclopride images, and on [18F]FDG data
of QA-lesioned rats. Spatially normalized images were
masked to remove extracerebral signals that would disrupt
the global normalization. All images were smoothed with an
isotropic Gaussian kernel of 1.6 mm. For analysis of
absolute [18F]MK-9470 receptor binding, no proportional
scaling was used and an analysis threshold of 0.8 of the mean
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image intensity was applied. To study regional [18F]MK-9470
uptake, proportional scaling was used. SPM analysis of
absolute parametric D2 binding data was performed without
global normalization and with an absolute analysis threshold
of –infinity (i.e. whole-brain analysis), while [18F]FDG data
were proportionally scaled with an analysis threshold of 80%
to exclude white matter and ventricular activity.
To minimize false-positive findings, T-map data were
interrogated at a peak level of p<0.005 (uncorrected) and
extent threshold kE >200 voxels (1.6 mm
3), as described
previously [30]. Only those clusters that were significant at
the p<0.05 (corrected) level were considered.
In addition, a voxel-based correlation analysis between
relative [18F]MK-9470 uptake/[18F]FDG data and the fol-
lowing covariates was performed within the QA-lesioned
group: (1) striatal [11C]raclopride binding to characterize D2
impairment and (2) the number of net ipsiversive turnings. A
correlation analysis between relative [18F]MK-9470 uptake
and [18F]FDG was carried out voxel-by-voxel wise using the
BPM toolbox for SPM2 [31]. D2 values were determined by
a predefined volume of interest (VOI) analysis based on
definition on the Paxinos atlas [24]. For D2 impairment, the
striatal affected to non-affected side BI ratio was obtained.
D2 impairment, FDG data and relative [
18F]MK-9470 uptake
were expressed as percentage of normal values.
General statistics
Conventional statistics were carried out using STATISTICA
v8.0 (StatSoft, Tulsa, OK, USA). Behavioural outcomes
and body weight gain were analysed using unpaired t tests.
Significance was defined at the 95% probability level. Data
are mean ± SD.
Results
Subjects and behavioural data
PBS- and QA-infused rats showed the same pattern of
body weight gain during the experiment (body weight gain
after 24 h: −2±1 vs −14±2 g, p<0.05, and after 4 weeks: 62±
20 vs 65±1 g, NS). No significant differences in the time of
recovery from anaesthesia (5.6±1.8 vs 5.5±1.1 min) were
found between PBS- and QA-infused rats. After surgery,
QA-lesioned rats displayed, among others, head nodding,
rolling and circling behaviour, with the net ipsiversive
turnings after amphetamine administration significantly
different from sham controls 4 weeks post-lesioning (151±
23 vs 8±6, p<0.05).
SPM analysis
Absolute [18F]MK-9470 binding values were not signifi-
cantly different between QA-lesioned rats and control
animals. Average cross-sectional small animal PET images
of absolute [18F]MK-9470 binding in controls and HD rats
are shown in Fig. 1. As can be seen from this figure, the
pattern of [18F]MK-9470 uptake observed in the rat control
brain is consistent with that previously reported ex vivo
Fig. 1 Average cross-sectional small animal PET images, coregistered
to MRI (a), of [18F]MK-9470 binding (b), glucose metabolism (c) and
[11C]raclopride binding in the rat brain of sham-operated animals (left)
and QA-lesioned rats (right). Colour bars indicate SUV values for
[18F]MK-9470, relative intensities for [18F]FDG and binding indices
for the dopamine D2 receptor. Intersection points of 3 planes have
been set to the mid-striatal level of the left hemisphere [i.e. (x, y, z)=
(3.4, −0.2, −6.0, Paxinos coordinates)]. Images are oriented in
neurological convention
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[12], i.e. a fairly homogeneous and high uptake in the
cortex, cerebellum and caudate-putamen.
When looking at regional changes by relative scaling
to the global mean tracer binding, [18F]MK-9470 values
were decreased in the ipsilateral caudate-putamen by 7%
(p<2.10−5). Also, glucose metabolism and D2 receptor
binding were reduced in this region by 35 and 77%,
respectively (all p<2.10−11). An increase for each of these
markers was observed on the contralateral side (>5%, all
p<7.10−4). The contralateral increase in relative metabolism
Fig. 2 Coronal brain sections
showing overlays on the regions
where a statistically significant
increase (red) and decrease
(blue) in relative [18F]MK-9470
binding (a), D2 receptor binding
(b) and relative glucose
metabolism (c) were observed in
QA-lesioned rats (figure given
at pheight<0.005 uncorrected) as
compared to controls.
Significance is shown with a T
statistic colour scale, which
corresponds to the level of
significance at the voxel level.
The distance between the
sections is 1.00 mm with the
position relative to the bregma
(positive values for sections
anterior to the bregma) on top of
the sections in the left column.
Images are oriented in
neurological convention. The D2
receptor deficit is located mainly
in the anterior part of the
caudate-putamen, which is in
correspondence to the site of
injection. The contralateral
cluster of relative glucose
metabolism encompasses the
caudate-putamen, hippocampus,
thalamus and sensorimotor
cortex
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extended towards the contralateral hippocampus, thalamus
and sensorimotor cortex (+5.8±1.9%, p=1.10−6).
Statistical parametric maps of [18F]MK-9470, [11C]
raclopride and [18F]FDG analysis are shown in Fig. 2.
Average cross-sectional small animal PET images of
glucose metabolism and [11C]raclopride BI in controls and
QA-lesioned rats are shown in Fig. 1.
Relative [18F]MK-9470 binding was also increased in
the cerebellum (+6.9±3.3%, p=2.10−5), where it was
inversely correlated to the number of ipsiversive turnings
(r=−0.94, p=7.10−6; Fig. 3a, b). No homologous regional
correlations of [18F]FDG and [11C]raclopride with relative
[18F]MK-9470 uptake were observed. Relative [18F]FDG
values of the ipsilateral caudate-putamen were positively
correlated with D2 impairment (r=0.92, p=9.10
−5; Fig. 3c,
d). Detailed cluster peak locations and p values of SPM
analyses are shown in Table 1.
Discussion
Neurodegenerative diseases such as HD are characterized by
gradually evolving selective neuronal death. Animal models
using neurotoxins that produce similar patterns of neuronal
degeneration may yield important information to elucidate its
aetiology and may be used to assess neuroprotective/
neuromodulatory approaches. In HD, much interest has
recently been focused on the ECS as alterations in CB1
receptor-mediated brain signalling might be related to
hyperkinesia, typical of the earliest phase of the disease, or
might be involved in the process of pathogenesis itself [32].
In this study, we have characterized CB1 receptor
alterations for the first time in vivo in QA-lesioned rats of
HD using [18F]MK-9470 and small animal PET. A whole-
brain characterization of CB1 receptors in this model is
valuable and necessary prior to starting drug treatment [9].
Fig. 3 a, c Coronal, transverse and sagittal brain sections with overlay of
the cluster with decreased relative [18F]MK-9470 binding (a) and
decreased relative [18F]FDG (c), expressed as percentage of controls, in
relation to rotational behaviour (net ipsiversive turnings) and D2
impairment for the QA group, respectively. Images are oriented in
neurological convention. b Scatter plot of relative [18F]MK-9470 uptake
at the maximal peak location of the cerebellum in relation to ipsiversive
turning behaviour of QA-lesioned rats. d Scatter plot of relative [18F]FDG
uptake at the maximal peak location of the lesioned caudate-putamen in
relation to D2 impairment of QA-lesioned rats, expressed as striatal
affected to non-affected side BI ratio
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Compared with sham controls, QA-infused rats showed
an in vivo decrease in CB1 receptor binding in the lesioned
caudate-putamen. Reductions in CB1 receptor levels of this
region are in line with ex vivo samples of HD models at
early and late stages of the disease. Lastres-Becker et al.
demonstrated, in the absence of neuronal loss, a 30%
reduction in the striatal CB1 receptor density of HD94
transgenic mice using [3H]CP55,940 autoradiography [5].
This reduction became more severe in 3-NP-treated rats
when striatal degeneration was evident, presumably as a
mere side effect caused by the progressive destruction of
medium spiny GABAergic neurons [10]. We reported in the
present study merely modest CB1 receptor loss in the QA
model, despite also evidence of prominent degeneration in
these animals, as reflected by D2 receptor imaging [33]. It
appears from our findings as if CB1 receptors try to restore
basal levels, but remain insufficient as mentioned before. In
the normal caudate-putamen, CB1 receptors are expressed
on presynaptic glutamatergic terminals originating in the
cortex [34, 35]. In experimental and human HD, cortico-
striatal glutamatergic transmission is severely impaired (for
review see [36]), and QA lesions result in a secondary
dying back of these terminals [37]. Relative upregulation of
this CB1 receptor population could conceivably represent a
compensatory response, damping the excessive cortico-
striatal glutamatergic drive that results from QA infusion
[38] and reducing the excitotoxic mechanisms underlying
HD [39]. However, within the caudate-putamen, CB1
receptors are also expressed on striatal GABAergic inter-
neurons that are labelled with parvalbumin and a few
interneurons of the cholinergic population [40], from which
their contribution to the observed effect cannot be excluded.
Other contributing mechanisms may be changes in receptor
affinity or in conformational state.
No correlation of this striatal CB1 receptor deficiency with
disease severity, measured by [18F]FDG and [11C]raclopride,
was observed. In patients and animals with HD, metabolic
abnormalities and reductions in dopamine binding are well
described in striatal and extrastriatal regions, progressively
decreasing upon symptom severity [18, 19, 41–45]. Here,
[18F]FDG values of the caudate-putamen were higher than,
but positively correlated to D2 impairment. Generally, [
18F]
FDG uptake is a correlate of neuronal activity [46], but cellular
metabolic decreases may also in part be compensated by [18F]
FDG uptake in reactive microglia, as has previously been
shown in this model [47, 48].
Interestingly, in the current study, the unilateral QA
lesion also causes CB1 receptor-related abnormalities in the
intact hemisphere, parallel to glucose metabolism and D2
receptor binding. This observation suggests the occurrence
of adaptive changes in the plasticity of the basal ganglia
circuitry. Reactive compensation of the contralateral hemi-
Table 1 Peak locations for the clusters in the group comparison and correlation analysis (at pheight≤0.005 uncorrected, kE>200)
Cluster level Voxel level Structure Name
pcorr kE T puncorr Intensity difference (%) x y z
Categorical analysis: [18F]MK-9470
QA>PBS <0.001 13498 6.82 <0.001 +6.9 4.2 −10.4 −4.0 Cerebellum
5.56 <0.001 2.6 −7.2 −2.2
5.36 <0.001 0.2 −14.8 −6.2
<0.03 2048 4.45 <0.001 +5.1 −5.0 0.2 −3.2 Primary visual cortex and
contralateral caudate-putamen3.94 <0.001 −1.2 −2.0 −4.2
3.74 ≤0.001 −2.4 −0.6 −3.6
QA<PBS <0.01 2523 5.41 <0.001 −6.9 1.4 −1.4 −4.0 Ipsilateral caudate-putamen
3.81 ≤0.001 4.0 −2.8 −3.8
2.97 ≤0.004 4.2 −0.4 −1.0
Correlation analysis: negative correlation with net ipsiversive turnings
<0.03 311 8.48 <0.001 - 2.8 −12.4 −6.0 Cerebellum
Categorical analysis: [11C]raclopride
QA>PBS ≤0.002 1635 4.44 <0.001 +34.6 −2.2 0.4 −2.6 Contralateral caudate-putamen
QA<PBS <0.001 56622 14.02 <0.001 −77.1 6.2 2.8 −9.6 Ipsilateral caudate-putamen
Categorical analysis: [18F]FDG
QA>PBS <0.001 42077 6.78 <0.001 +5.8 −5.8 −4.8 −2.6 Association cortex
QA<PBS <0.001 28854 16.17 <0.001 −35.1 3.2 0.2 −5.4 Ipsilateral caudate-putamen
Correlation analysis: positive correlation with D2 impairment
<0.05 552 6.45 >0.001 - 3.2 0.0 −7.4 Ipsilateral caudate-putamen
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sphere with regard to D2/CB1 receptors and glucose
metabolism has not been demonstrated before in unilateral
HD models by histology and imaging techniques. Previous
animal experiments made use of between-hemisphere
comparisons or only focused on the lesioned side in
comparison to control data [19, 48]. Notably, studies with
unilateral intranigral 6-hydroxydopamine (6-OHDA) applica-
tion to model Parkinson’s disease (PD) found similar findings
of increased D2 receptor densities in the contralateral
caudate-putamen [49, 50]. There is also histologic evidence
for interhemispheric projections from the striatum to the
motor cortex [51], and upon lesioning, evidence of increased
sprouting from intact to damaged hemispheres [52].
From our observations, it also appears as if reactive
compensation is not limited to striatal structures only. In the
QA model, we also found increased [18F]MK-9470 tracer
activity in the cerebellum, which inversely correlates to the
number of ipsiversive turnings, suggesting that animals
with the highest binding were related to a better functional
outcome. In agreement with this finding, reduced CB1
receptor levels in the cerebellum have been shown to be
associated with locomotor hyperactivity in congenitally
hypothyroid rats [53]. Motor hyperactivity is also a well-
characterized feature observed in QA-treated animals, which
appears already 2 weeks post-lesioning and lasts up to
6 months [54]. Here, the amphetamine-induced asymmetry
test has been performed 4 weeks following the adminis-
tration of QA intrastriatally, which is a time interval of
7–9 weeks from the [18F]MK-9470 PET imaging. Putative
alterations of the lesions occurring within that time interval
are unlikely to have affected the behavioural outcome. It has
clearly been shown that the lesions induced by QA result in
stable ipsiversive turnings over time (range: 2–9 weeks) [55,
56]. Also, the striatal D2 receptor asymmetry, underlying this
behavioural effect, has been shown to reach a steady state,
starting 16 days post-administration [19]. The striatal
affected to non-affected side BI ratio of this study was also
nearly constant among subjects between 15 and 25 weeks
y ¼ 0:0042xþ 0:1875ð Þ.
In the design of this study, we have explicitly set the aim
to investigate CB1 receptor network alterations by using
both absolute and relative [18F]MK-9470 measurements. It
is known that there is a higher physiologic interindividual
variability of absolute regional [18F]MK-9470 determina-
tions in the human brain, in the order of several tens of per
cent [14, 57]. Relative measurements have the advantage of
being much more sensitive, allowing changes of 5–10% to
be measured using SPM [58], as proven here.
Although QA neurotoxicity provokes loss of medium-
sized spiny neurons in the injected striatal region,
associated with motor hyperactivity [54] and spatial
learning deficits [59], comparable to HD, it does not
replicate the genetic hallmark underlying this disorder. This
finding, together with the suggestion that (modest) species-
specific differences exist in the brain CB1 receptor distribu-
tion [14], reinforce the importance of translational research.
Therefore, careful comparison to the human condition is
needed to assess the in vivo validity and functional
significance of our current findings, especially on the ECS
which may open perspectives for neurochemical modulation
of this currently untreatable neurodegenerative disorder.
In the present study, we have used QA rats because of the
smaller brain size in transgenic mice which decreases
sensitivity due to spatial resolution limits of small animal
PET. In comparison to human studies, these QA rats received
a relatively high dose of radiotracer. As the average weight of
humans vs rats shows a ratio of approximately 300, care needs
to be taken not to induce pharmacological effects. For the
specific activity administered, the calculated % receptor
occupancy of [11C]raclopride was found to be in the range
of 0.8–11%. This is still unlikely to induce a major
pharmacological effect, such as dyskinesia, observed at an
occupancy of over 50% for dopamine D2 receptors. Also for
[18F]MK-9470, occupancies that are well below the phar-
macological threshold were obtained (1–10 %) [60].
In conclusion, this in vivo study suggests modest regional
changes in endocannabinoid transmission specific for CB1
receptors in the QA rodent model of HD and points
towards a compensatory role of the cerebellum. Our
results additionally demonstrate the occurrence of functional
plasticity in the QA lesion model on metabolism, D2 and CB1
neurotransmission, which implicates the need for carefulness
when using the contralateral side as control condition.
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